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Imaging currently play an important role in routine clinical 
care and clinical trials in triaging patients to appropriate 
management and in monitoring patients on therapy. In terms 
of treatment assessment it is essential for imaging markers to 
be consistent, reproducible and validated. Standardized 
response assessment based on morphological change, such as 
RECIST 1.1 is well established in the clinical trial setting 
although its limitations for therapies beyond standard 
chemotherapy are recognised e.g. immunotherapy, and for 
which alternative response criteria have been proposed. 
Computed tomography (CT) remains that most commonly 
performed imaging modality due to its high spatial resolution 
and its cost-effectiveness, but positron emission tomography 
(PET) and magnetic resonance imaging (MRI) have advantages 
in their capability to image beyond morphology.  
Measurement of glucose metabolism, cell proliferation, 
hypoxia, and vascularisation is now possible in clinical 
practice as well as quantification of their spatial variation, 
providing an imaging phenotype that is likely to be more 
beneficial than simple biomarkers e.g. size in predicting 
individual patient response to therapy. These imaging 
methods can also be integrated with genomic and 
pathological data allowing a comprehensive approach to 
address the clinical need towards individualisation of therapy 
in the future.  
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In personalized medicine, early prediction of pathologic 
complete response for locally advanced rectal cancer (LARC) 
patients is essential to tailor treatment. The standard 
treatment for LARC patients consists of preoperative 
chemoradiotherapy (CRT) followed by surgery, with a 
complete response being observed in 15-30% of the patients 
after the neo-adjuvant treatment. Overtreatment of 
complete responders could be avoided if an accurate 
prediction of pCR is available, by selecting a wait-and-see 
policy instead of surgery after CRT, and thereby reducing 
treatment related complications. Further treatment 
strategies based on the prediction of pCR include a 
radiotherapy boost after CRT for patients with good response 
to achieve a higher complete response rate, and additional 
chemotherapy after initial CRT for the worst responding 
patients. 
In recent years, [18F] fluoro-2-deoxy-D-glucose positron 
emission tomography (FDG-PET) imaging has been 
increasingly used for decision support, treatment planning 
and response monitoring during radiotherapy. Radiomics 
(www.radiomics.org; animation: 
http://youtu.be/Tq980GEVP0Y) is a high throughput 
approach to extract and mine a large number of quantitative 
features from medical images, characterizing tumor image 
intensity, shape and texture. The core hypothesis of 
radiomics is that it can provide valuable diagnostic, 
prognostic or predictive information. FDG-PET radiomics may 
therefore facilitate early and accurate prediction of tumor 
response to treatment to identify LARC patients eligible for a 
wait and see or organ preserving approach, or patients who 
may benefit from treatment intensification. 
This presentation will focus on the methodology of, and 
technical challenges in, the development and validation of a 
predictive PET radiomic model for pCR in LARC patients, 
illustrated with recent data. 
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In vivo treatment verification is highly desirable, especially 
but not only in particle therapy where uncertainties in the 
particle range can compromise the physical advantage of this 
treatment modality. Existing measurement techniques for 
range measurements exploit physical effects, in particular 
secondary radiation that is produced by the proton beam, for 
example through activation of positron emitters, or prompt 
gamma radiation. Also biological effects caused by the 
irradiation can be used for in vivo treatment verification, if a 
functional imaging method is available to visualize the 
effect. 
One prominent example for biology-driven range verification 
is an irradiation-induced change in contrast-enhanced MRI of 
the liver. A strong systematic decrease in uptake of the 
hepatobiliary-directed contrast agent Gd-EOB-DTPA has been 
shown in irradiated healthy liver tissue 6-9 weeks after 
irradiation [1-3] using different treatment modalities 
(brachytherapy, stereotactic body radiation therapy with 
photons and protons). The underlying mechanism seems to be 
based on a pro-inflammatory reaction of the irradiated liver 
tissue resulting in a downregulation of the Gd-EOB-DTPA 
uptake transporters and an upregulation of the respective 
excretion transporters [4].  
In a prospective clinical study, carried out at Massachusetts 
General Hospital in Boston (USA), we investigated whether 
MRI of the liver can be used for in vivo dosimetric verification 
already during the course of hypo-fractionated proton 
therapy of liver metastases (5 fractions within 2 weeks). In 
contrast to the previously found late changes weeks after the 
end of treatment that were seen in all patients, for the early 
Gd-EOB-DTPA enhanced MR imaging large inter-patient 
variations were found. For 10 patients, strong or moderate 
signal changes were detected for 2 and 3 patients, 
respectively. For 5 patients no dose-correlated early signal 
change was found at all. This qualitative scoring was 
consistent with a quantitative voxelwise dose to signal 
change correlation. The analysis of additional parameters 
that could potentially explain inter-patient variations (e.g. 
dose delivered at time of MRI scans, several timing 
parameters, liver function parameters and circulating 
biomarkers of inflammation determined from blood samples 
taken before and during treatment) revealed no clear 
correlation or trend with the strength of the signal decrease. 
Hence, irradiation-induced effects in the liver can be 
detected with Gd-EOB-DTPA enhanced MRI within a few days 
after proton irradiation in a subgroup of patients. As all 
patients possessed a signal decrease in late follow up scans, 
only the early dynamics of the liver response is influenced by 
these inter-patient variations. The reason for these large 
variations in early response is not yet fully understood and 
needs further investigation.  
This presentation will cover a brief overview of biological 
effects used for treatment verification and will then focus on 
the irradiation-induced signal change in Gd-EOB-DTPA 
enhanced MRI of the liver. The hypothesis for the biological 
mechanism, the available data for late and early MRI signal 
changes will be presented and open questions will be 
discussed.  
 
 
 
 
